Tenax Therapeutics’ (TENX) “Outperform” Rating Reiterated at William Blair

Tenax Therapeutics (NASDAQ:TENX)‘s stock had its “outperform” rating reiterated by analysts at William Blair in a research report issued to clients and investors on Monday,RTT News reports.

Separately, Leerink Partners set a $20.00 price target on Tenax Therapeutics in a research note on Monday. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Tenax Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Price Performance

Shares of NASDAQ:TENX opened at $6.19 on Monday. The business’s 50 day simple moving average is $6.44 and its 200-day simple moving average is $5.21. Tenax Therapeutics has a 12 month low of $2.77 and a 12 month high of $7.89.

Institutional Investors Weigh In On Tenax Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Two Sigma Investments LP purchased a new stake in Tenax Therapeutics in the 4th quarter valued at approximately $84,000. Millennium Management LLC purchased a new stake in Tenax Therapeutics in the 4th quarter valued at approximately $166,000. Janus Henderson Group PLC purchased a new stake in Tenax Therapeutics in the 4th quarter valued at approximately $1,026,000. Geode Capital Management LLC lifted its stake in Tenax Therapeutics by 32.4% in the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after buying an additional 5,964 shares in the last quarter. Finally, Sphera Funds Management LTD. purchased a new stake in Tenax Therapeutics in the 3rd quarter valued at approximately $101,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.